Gilead received FDA accelerated approval for Hepcludex, the first U.S. treatment for chronic hepatitis delta virus. The EMA also recommended Trodelvy for first-line metastatic triple-negative breast cancer. Gilead completed a $5 billion Tubulis acquisition and presented strong oncology data at ASCO and EHA. A Maxim upgrade and positive HIV pipeline updates from the RBC conference further boosted sentiment.